GBIM:OTCMKTS
GlobeImmune Inc
0,00010 US$
0,00%
(0,00) 1 Д
29. сеп, 15:48:52 GMT-4 · USD
search
Сви симболи
| Симбол | Цена | Промена | % промене |
|---|
insights_autoГенеришу се најзначајнији увиди за GBIM...
Трж. капитализација
580,00
Прос. количина
1,74 хиљ.
Количина
0,00
Највиша у 52 недеље
0,04 US$
Најнижа у 52 недеље
0,00 US$
Акцијски капитал
5,75 мил.
Бр. запослених
22
Трж. капитализација
580,00
Прос. количина
1,74 хиљ.
Количина
0,00
Највиша у 52 недеље
0,04 US$
Најнижа у 52 недеље
0,00 US$
Акцијски капитал
5,75 мил.
Бр. запослених
22
Вести
Из веб-извора и од партнера за вести
Blic
·
пре 7 сати
Američke berze počele nedelju neujednačeno! Nafta sve skuplja: Investitori čekaju važne izveštaje
National Hog Farmer
·
пре 1 сата
NYSE owner plans futures for livestock in a bid to challenge CME Group
Stock Titan
·
пре 1 сата
A new drone interceptor is designed to counter one-way attack drones.
GlobeNewswire
·
пре 1 сата
Primech Holdings (Nasdaq: PMEC) to Present at LD Micro Main
Профил
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
GlobeImmune Inc – основни подаци
Главни извршни директор-
Запослени22
Основано1. 1. 1995.
СедиштеЛуисвил, Колорадо, Сједињене Државе
Сектор-
Веб-сајтglobeimmune.com